1. Home
  2. GLUE vs LNKB Comparison

GLUE vs LNKB Comparison

Compare GLUE & LNKB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GLUE
  • LNKB
  • Stock Information
  • Founded
  • GLUE 2019
  • LNKB 2018
  • Country
  • GLUE United States
  • LNKB United States
  • Employees
  • GLUE N/A
  • LNKB N/A
  • Industry
  • GLUE Biotechnology: Pharmaceutical Preparations
  • LNKB
  • Sector
  • GLUE Health Care
  • LNKB
  • Exchange
  • GLUE Nasdaq
  • LNKB Nasdaq
  • Market Cap
  • GLUE 308.8M
  • LNKB 270.4M
  • IPO Year
  • GLUE 2021
  • LNKB N/A
  • Fundamental
  • Price
  • GLUE $7.72
  • LNKB $7.06
  • Analyst Decision
  • GLUE Buy
  • LNKB Strong Buy
  • Analyst Count
  • GLUE 2
  • LNKB 1
  • Target Price
  • GLUE $13.50
  • LNKB $9.00
  • AVG Volume (30 Days)
  • GLUE 2.5M
  • LNKB 60.5K
  • Earning Date
  • GLUE 11-06-2025
  • LNKB 10-27-2025
  • Dividend Yield
  • GLUE N/A
  • LNKB 4.25%
  • EPS Growth
  • GLUE N/A
  • LNKB N/A
  • EPS
  • GLUE 0.29
  • LNKB 1.01
  • Revenue
  • GLUE $177,986,000.00
  • LNKB $121,982,000.00
  • Revenue This Year
  • GLUE $83.76
  • LNKB $18.26
  • Revenue Next Year
  • GLUE N/A
  • LNKB N/A
  • P/E Ratio
  • GLUE $26.24
  • LNKB $6.99
  • Revenue Growth
  • GLUE 2990.57
  • LNKB 79.01
  • 52 Week Low
  • GLUE $3.50
  • LNKB $6.09
  • 52 Week High
  • GLUE $12.40
  • LNKB $7.98
  • Technical
  • Relative Strength Index (RSI)
  • GLUE 64.92
  • LNKB N/A
  • Support Level
  • GLUE $7.24
  • LNKB N/A
  • Resistance Level
  • GLUE $7.87
  • LNKB N/A
  • Average True Range (ATR)
  • GLUE 0.40
  • LNKB 0.00
  • MACD
  • GLUE 0.02
  • LNKB 0.00
  • Stochastic Oscillator
  • GLUE 75.25
  • LNKB 0.00

About GLUE Monte Rosa Therapeutics Inc.

Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.

About LNKB LINKBANCORP Inc.

Linkbancorp Inc operates in the banking industry. It provides banking services for individuals and businesses such as commercial lending, non-profit banking, treasury management, deposits and loans. Company portfolio segments includes: Agriculture and farmland, Construction, Commercial & industrial, Commercial real estate, Residential real estate, Municipal, customers and Other loans.

Share on Social Networks: